INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi ®, a biosimilar referencing Humira ® 1 (adalimumab), for the treatment of ...
Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...
Authors of an article in JAMA Dermatology investigated the differences in effectiveness between adalimumab biosimilars (Amjevita and Imraldi) and the adalimumab originator for psoriasis. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback